1
Tarran Jones
Mary M Bendig, Olivier J Leger, Jose Saldanha, S Tarran Jones, Ted A Yednock: Humanized antibodies against leukocyte adhesion molecule VLA-4. Athena Neurosciences, Townsend & Townsend & Crew, November 24, 1998: US05840299 (86 worldwide citation)

The invention provides humanized immunoglobulins that specifically bind to the VLA-4 ligand, and methods of treatment using the same. The methods are particularly useful for treatment of multiple sclerosis.


2
Tarran Jones
Mary M Bendig, Olivier J Leger, Jose Saldanha, Tarran S Jones, Ted A Yednock: Methods of inhibiting alpha-4-dependent interactions with VCAM-1 with anti-VLA-4 antibodies. Elan Pharmaceuticals, Crowell & Moring, August 21, 2012: US08246958 (33 worldwide citation)

The invention provides methods of treatment using humanized immunoglobulins that specifically bind to alpha-4 integrin. The methods are useful for treatment of asthma, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, transplant rejection, graft versus host ...


3
Tarran Jones
Paul D Ponath, Douglas J Ringler, S Tarran Jones, Walter Newman, José Saldanha, Mary M Bendig: Humanized immunoglobulin reactive with α4β7 integrin. Millennium Pharmaceuticals, Hamilton Brook Smith & Reynolds P C, December 12, 2006: US07147851 (32 worldwide citation)

The present invention relates to humanized immunoglobulins having binding specificity for α4β7 integrin, comprising an antigen binding region of nonhuman origin (e.g., rodent) and at least a portion of an immunoglobulin of human origin (e.g., a human framework region, a human constant region). In on ...


4
Tarran Jones
Britta Hardy, Steven Tarran Jones, Leah Klapper: Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency. CureTech, Mor Research Applications, Winston & Strawn, February 19, 2008: US07332582 (21 worldwide citation)

The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, and is capable of eliciting an anti-tumor effect upon administration t ...


5
Tarran Jones
David M Hilbert, Tarran Jones, David G Williams: Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease. Medimmune, Aeres Biomedical, Jones Day, November 9, 2010: US07829086 (17 worldwide citation)

The present invention provides chimeric and humanized versions of anti-CD22 mouse monoclonal antibody, HB22.7. The anti-CD22 antibodies of the invention comprise four human or humanized framework regions of the immunoglobulin heavy chain variable region (“VH”) and four human or humanized framework r ...


6
Tarran Jones
Britta Hardy, Steven Tarran Jones, Leah Klapper: Humanized immunomodulatory monoclonal antibodies for the treatment of immunodeficiency. CureTech, Mor Research Applications, Winston & Strawn, July 19, 2011: US07981416 (9 worldwide citation)

The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, particularly T cells, and is capable of eliciting an anti-tumor effect ...


7
Tarran Jones
Britta Hardy, Steven Tarran Jones, Leah Klapper: Human immunomodulatory monoclonal antibodies for the treatment of cancer. CureTech, Mor Research Application, Winston & Strawn, April 28, 2009: US07524498 (7 worldwide citation)

The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, particularly T cells, and is capable of eliciting an anti-tumor effect ...


8
Tarran Jones
Roger A Sabbadini, William A Garland, Genevieve Hansen, Steven Tarran Jones, David Gareth Williams: Compositions and methods for binding sphingosine-1-phosphate. Lpath, BioTechnology Law Group, Daniel M Chambers, November 9, 2010: US07829674 (4 worldwide citation)

The present invention relates to anti-S1P agents, for example, humanized monoclonal antibodies, and their uses for detection of S1P or for treatment of diseases and conditions associated with S1P.


9
Tarran Jones
Gregory J LaRosa, Christopher J Horvath, Walter Newman, S Tarran Jones, Siobhan H O Brien, Theresa O Keefe: Humanized anti-CCR2 antibodies and methods of use therefor. Millennium Pharmaceuticals, Lando & Anastasi, July 28, 2009: US07566450 (4 worldwide citation)

The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the intera ...


10
Tarran Jones
Gregory J LaRosa, Christopher Horvath, Walter Newman, S Tarran Jones, Siobhan H O Brien, Theresa O Keefe: Humanized anti-CCR2 antibodies and methods of use therefor. Millennium Pharmaceuticals, Lando & Anastasi, July 24, 2012: US08227211 (3 worldwide citation)

The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the intera ...